
Takeda forecasts $1.7B loss after Shire integration; Flagship’s preclinical biotech Axcella closes IPO with $71M+ haul
? Takeda?s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it?s giving analysts a negative surprise. Citing costs for integrating the Ireland-based Shire, the Japanese drugmaker forecasts an operat… […]